Oct. 14 at 7:24 PM
$MYNZ
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
article : link
https://finance.yahoo.com/news/mainz-biomed-partners-liquid-biosciences-080100831.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACKnpS-Lcr-3EF8lJgtNUDY2qr7ZOTjAO3p5lnUgX5gEQcmZTHFzpgDz4UrMo9bjEI6qm4FtGkRkdNie_wYi_z5EMh7Kb2dELFyQxj1nswqpRvwMZB74stshuxMlsF0E3QGKmEuTQmtVi0iOgT-G5LyAb794cYaN20UBhgs2Bgbw
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis
BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the expansion of its collaboration with Liquid Biosciences to Mainz Biomed’s next-generation detection test for pancreatic cancer. The companies will leverage Liquid Biosciences proprietary AI analysis technology platform (EMERGE) to expand and optimize the selection of novel biomarkers for PancAlert.